Answers are grounded in this paper and cite their sources.
In 1966, Laron first reported patients with clinical and laboratory signs of growth hormone deficiency who also had extremely high levels of immunoreactive serum growth hormone. Extensive biochemical, hormonal, and molecular study of these patients identified the cause as a deficiency of growth hormone receptors. Laron syndrome is sometimes called growth hormone insensitivity (GHI) or growth hormone receptor deficiency. More than 200 patients have now been reported.Laron syndrome, also known as GHI, is rarely reported in Southeast Asian countries, with the only previously reported cases from Japan and India. We present a case of Laron syndrome from Thailand with the clinical features of the syndrome, but whose laboratory studies are distinct from typical GHI.A 12-year-old Thai-Muslim girl presented with severe short stature and bone age of 4 years. She was a term birth by normal delivery, with a birth weight of 2,600 g. Birth length was not recorded. Subsequent growth was very poor. She weighed 3 kg at 6 months, 3.5 kg at 1 year and 4 kg at 2 years. Developmental milestones were delayed in the motor area but normal for language. There was no history of seizure, night sweats or unusual behavior. She entered primary school at age 6 and has done satisfactory work. Physical examination revealed an extremely small girl with a weight of 10 kg (–3.7 SDS), height of 85 cm (–9.3 SDS), and a head circumference of 47 cm. Upper to lower segment ratio was 1.15 (45 vs. 39 cm). Her facial appearance was characteristic, with prominent forehead, deep set eyes, flat nasal bridge and maxillary hypoplasia. Her skin was dry and thin. Other features were normal.Blood work and thyroid function were normal. Random serum growth hormone level (RIA method) was 5.19 ng/ml. Growth hormone provocative test (clonidine 100 µg/m2) revealed rising of growth hormone level from the baseline of 10.22 to 22.7 ng/ml. Frozen serum was sent to the USA for IGF-I, IGF-BP3 and GHBP measurements. Results are shown in table 1.The typical features of Laron syndrome include severe growth retardation, characteristic craniofacial appearance, low IGF-I and IGF-BP3 despite elevated serum growth hormone concentration, low GHBP levels and no response of IGF-I and IGF-BP3 after GH administration. This patient is not typical in having a normal level of GHBP and a modest response of IGF-I and IGF-BP3 after GH administration. There now are several reported cases of typical clinical appearance GHI patients with normal GHBP levels (approximately 20% of proven cases of Laron syndrome in a large European cohort). Transmembrane or intracellular defects of the GHR, or even extracellular defects which affect dimerization of the GHR, may be responsible, or there may also be a postreceptor defect. Definitive diagnosis of GHR defect requires identification of the specific molecular defect of the GHR. Careful consideration is needed because polymorphism of this gene may occur without any phenotypic sequelae.Definitive diagnosis of GHRD may require clinical phenotype, a decrease in IGF-I and IGF-BP3 levels, and identification of an abnormality of the GHR gene. In our patient, the clinical phenotype along with the low IGF-I and IGF-BP3 are consistent with the diagnosis.
No takes yet. Share an insight, caveat, or question.
Jaruratanasirikul et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: